62,654 Shares in Danaher Corporation $DHR Acquired by Portland Investment Counsel Inc.

Portland Investment Counsel Inc. acquired a new stake in shares of Danaher Corporation (NYSE:DHR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 62,654 shares of the conglomerate’s stock, valued at approximately $11,934,000. Danaher accounts for 3.3% of Portland Investment Counsel Inc.’s portfolio, making the stock its 9th biggest holding.

Several other hedge funds also recently bought and sold shares of DHR. EP Wealth Advisors LLC purchased a new position in Danaher in the 2nd quarter worth about $3,807,000. Northwestern Mutual Wealth Management Co. boosted its position in Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after buying an additional 186,584 shares during the period. Puzo Michael J purchased a new stake in Danaher in the 2nd quarter valued at about $8,624,000. Legal & General Group Plc grew its stake in Danaher by 1.0% in the 4th quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate’s stock worth $1,029,061,000 after acquiring an additional 43,169 shares in the last quarter. Finally, Madison Asset Management LLC purchased a new position in shares of Danaher during the second quarter worth approximately $85,451,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.3%

NYSE:DHR opened at $219.42 on Monday. The stock has a market capitalization of $154.25 billion, a price-to-earnings ratio of 38.97, a PEG ratio of 2.72 and a beta of 0.78. Danaher Corporation has a 52 week low of $160.93 and a 52 week high of $242.80. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $195.80 and a 200 day moving average of $192.40.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the firm posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on DHR. Guggenheim decreased their price target on shares of Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, July 15th. Stifel Nicolaus reduced their price objective on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. DZ Bank started coverage on Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 target price for the company. Finally, Wells Fargo & Company lowered their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.